Seven years after the first gene-edited babies were revealed, biotech startup Manhattan Genomics is reviving the idea of ...

Azalea's first drug candidate is a CAR-T therapy for cancer and autoimmune conditions that turns immune cells into cancer ...

Cathy Tie, who launched her first biotech in SF's IndieBio, now leads Manhattan Genomics in controversial push to edit human ...

A new West Coast biotech has emerged into the busy in vivo cell therapy space, this time with the backing of Nobel Prize-winning CRISPR pioneer Jennifer Doudna, Ph.D. Azalea Therapeutics has bloomed ...

Both CRSP and NTLA are advancing in vivo gene editing therapies targeting large markets, with financial stability supporting ...

With $80 million in funding from a list of high-profile backers, the startup is developing bifunctional antibodies that drag ...

Health Secretary Robert F. Kennedy Jr. called the treatment 'a powerful glimpse into the future of personalized medicine' ...

Investors want their money to grow in some shape, form, or fashion with every stock they buy. However, I understand that ...

Lateone monsoon evening in Tiruppur, a textile buyer ran two fingers across a swatch he couldn’t quite place. It felt like ...

Attempting to cash in on what's likely to be a relatively short-lived mania isn't a good idea for most investors most of the ...

To solve this critical challenge, he founded Nephrogen in 2022, a biotech startup that uses AI and advanced screening to ...